SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sandu Pharmaceuticals informs about disclosure

25 Feb 2023 Evaluate

Sandu Pharmaceuticals has informed that it enclosed Trading Approval Letter received from BSE pertaining to application made by Company in respect of the Trading of 8,50,326 equity shares of Rs 10 each to be issued at premium of Rs 10.69 bearing distinctive numbers from 8810665 to 9660990 issued to Promoter and Non-Promoters on a preferential basis pursuant to conversion of 8,50,326 warrants.

The above information is a part of company’s filings submitted to BSE.

Sandu Pharmaceutical Share Price

41.41 -0.10 (-0.24%)
25-Jun-2026 14:26 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1862.00
Dr. Reddys Labs. 1347.95
Cipla 1442.70
Zydus Lifesciences 1100.30
Lupin 2349.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: